MedTrace Logo

Therapy De-escalation in Seminoma Stage IIA/B

NCT01593241 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-02-13

No results posted yet for this study

Summary

The main objective of this trial is to test the efficacy and safety of carboplatin chemotherapy and involved node radiotherapy in patients with stage IIA/B seminoma.

Conditions

  • Seminoma

Interventions

DRUG

Carboplatin

Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy

RADIATION

Involved node RT

Involved node RT

Sponsors & Collaborators

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Alexandros Papachristofilou, MD · University Hospital, Basel, Switzerland

  • Richard Cathomas, MD · Cantonal Hospital Graubünden

  • Jens Bedke, Prof · D - University Hospital Tübingen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-15
Primary Completion
2025-01-30
Completion
2025-01-30

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01593241 on ClinicalTrials.gov